Suspension of trading

ETFs Forte Biosciences

FBRX

US34962G2084

Market Closed - Nasdaq 06:00:00 27/08/26 am AEST			5-day change	1st Jan Change
76.99 ^USD	+0.03%		+0.09%	+182.32%

28/08	Argenx SE completed the acquisition of Forte Biosciences, Inc..	CI
27/08	Argenx Completes Acquisition of Forte Biosciences	MT

ETFs positioned on Forte Biosciences

Name	YTD change	Weight	AuM
ISHARES MICRO-CAP ETF - USD	+23.67%	0.06%	1,518 M€
AVANTIS U.S. SMALL CAP EQUITY ETF - USD	+24.50%	0.01%	3,154 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+13.15%	0%	692,025 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+12.02%	0%	7,793 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+14.57%	0%	14,144 M€
UPAR ULTRA RISK PARITY ETF - USD	+6.47%	0%	59 M€
ELM MARKET NAVIGATOR ETF - USD	+9.32%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+5.00%	0%	688 M€
DEFINED DURATION 20 ETF - USD	+14.42%	0%	19 M€
RPAR RISK PARITY ETF - USD	+4.95%	0%	580 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	+1.49%	0%	184 M€
CI GLOBAL CORE PLUS EQUITY ETF - CAD	0.00%	0%	43 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+2.74%	0%	267 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+9.33%	0%	176 M€
CAMBRIA TAX AWARE ETF - USD	+9.90%	0%	26 M€
AB US EQUITY ETF - USD	+10.26%	0%	727 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+16.27%	0%	12,086 M€
CAMBRIA US EW ETF - USD	+12.08%	0%	194 M€
DEFINED DURATION 5 ETF - USD	+1.60%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+10.70%	0%	146 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+11.27%	0%	513 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+14.04%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+15.17%	-.--%	62 M€

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Employees

Sector

More about the company